For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…
Liposomes have been used to improve the therapeutic index of new or established drugs by modifying drug absorption, reducing metabolism, prolonging biological half-life or reducing toxicity. Drug distribution is then controlled primarily by properties of the carrier and no longer by physico-chemical characteristics of the drug substance only. In a liposome drug product, the drug substance is contained in liposomes. Typically, water soluble drugs are contained in the aqueous compartment(s) and hydrophobic drugs are contained in the lipid layer(s) of the liposomes. Release of drugs from liposome formulations can be modified by the presence of polyethylene glycol and/or cholesterol or other potential additives in the liposome.
LPI (LP Information)' newest research report, the "Liposome Drug Delivery Industry Forecast" looks at past sales and reviews total world Liposome Drug Delivery sales in 2022, providing a comprehensive analysis by region and market sector of projected Liposome Drug Delivery sales for 2023 through 2029. With Liposome Drug Delivery sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Liposome Drug Delivery industry.
This Insight Report provides a comprehensive analysis of the global Liposome Drug Delivery landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Liposome Drug Delivery portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Liposome Drug Delivery market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Liposome Drug Delivery and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Liposome Drug Delivery.
The global Liposome Drug Delivery market size is projected to grow from US$ 3652.8 million in 2022 to US$ 8742.8 million in 2029; it is expected to grow at a CAGR of 8742.8 from 2023 to 2029.
Global Liposome Drug Delivery key players include Gilead Sciences, Pacira, Sun Pharmaceutical, Johnson & Johnson, Luye Pharma, etc. Global top five manufacturers hold a share about 60%. North America is the largest market, with a share about 40%, followed by Europe and Asia-Pacific, both with a share about 30 percent. In terms of product, Liposomal Doxorubicin is the largest segment, with a share about 40%. And in terms of application, the largest application is Cancer & Tumor Therapy, followed by Fungal Infection Therapy, etc.
This report presents a comprehensive overview, market shares, and growth opportunities of Liposome Drug Delivery market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
- Liposomal Doxorubicin
- Liposomal Amphoteracin B
- Liposomal Paclitaxel
- Others
Segmentation by application
- Fungal Infection Therapy
- Cancer & Tumor Therapy
- Others
This report also splits the market by region:
- Americas
- - United States
- - Canada
- - Mexico
- - Brazil
- APAC
- - China
- - Japan
- - Korea
- - Southeast Asia
- - India
- - Australia
- Europe
- - Germany
- - France
- - UK
- - Italy
- - Russia
- Middle East & Africa
- - Egypt
- - South Africa
- - Israel
- - Turkey
- - GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
- Gilead Sciences
- Pacira
- Sun Pharmaceutical
- Johnson & Johnson
- Luye Pharma
- Sigma-Tau
- Ipsen (Onivyde)
- CSPC
- Teva Pharmaceutical
- Novartis
- Fudan-Zhangjiang
Key Questions Addressed in this Report
What is the 10-year outlook for the global Liposome Drug Delivery market?
What factors are driving Liposome Drug Delivery market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Liposome Drug Delivery market opportunities vary by end market size?
How does Liposome Drug Delivery break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?